IQVIA

IQVIA Holdings Inc., headquartered in Durham, North Carolina, stands as a Fortune 500 and S&P 500 company that represents the convergence of data science, technology, and clinical expertise in healthcare. With approximately 88,000 employees operating across more than 100 countries, IQVIA has established itself as an indispensable partner to pharmaceutical companies, biotechnology firms, medical device manufacturers, and healthcare providers worldwide. The company's genesis traces back to two pioneering organizations: IMS Health, founded in 1954 as Intercontinental Marketing Services by Bill Frohlich and David Dubow, which revolutionized pharmaceutical market research and data analytics, and Quintiles, founded in 1982 by Dennis Gillings, a biostatistics professor who recognized the growing need for outsourced clinical research services within the pharmaceutical and biotechnology industries.

The 2016 merger of these two industry giants created a powerhouse valued at approximately $17.6 billion, combining IMS Health's unparalleled healthcare data assets with Quintiles' clinical research capabilities. This strategic union, completed in October 2016, brought together complementary strengths that positioned the combined entity to address the full therapeutic lifecycle from research and development through commercialization. On November 6, 2017, the company adopted the name IQVIA—a combination of 'I' from IMS Health, 'Q' from Quintiles, and 'VIA' meaning 'by way of'—symbolizing its mission to be the pathway to innovation in healthcare. Since the merger, IQVIA has consistently demonstrated strong financial performance, reporting $15.4 billion in revenue for fiscal year 2024, with operations spanning three core business segments: Technology & Analytics Solutions (TAS) accounting for 40% of revenue, Research & Development Solutions (R&DS) representing 55%, and Contract Sales & Medical Solutions contributing 5%.

IQVIA's competitive advantage lies in its unique combination of assets and capabilities. The company maintains one of healthcare's most comprehensive data repositories, with over 1.2 billion de-identified patient health records offering detailed insights into patient healthcare experiences across multiple touchpoints. This vast data asset, combined with proprietary analytics platforms and artificial intelligence capabilities, enables IQVIA to deliver insights that drive better decision-making for life sciences companies and healthcare providers. The company's technology portfolio includes advanced platforms for clinical trial management, real-world evidence generation, commercial analytics, safety and pharmacovigilance, and regulatory compliance. IQVIA's commitment to innovation is exemplified by its January 2025 partnership with NVIDIA to develop healthcare-grade AI models and agentic AI agents, building on the September 2024 launch of the IQVIA AI Assistant, which won the 2024 PM360 Innovation Award for Artificial Intelligence. These AI-powered solutions make complex analytics accessible through conversational interfaces and automate time-consuming workflows across the therapeutic lifecycle.

The company serves a diverse client base ranging from emerging biotechnology startups to global pharmaceutical giants, medical device manufacturers, payers, providers, and government agencies. IQVIA's services span the entire product lifecycle, from early-stage research and clinical trial design through regulatory approval, commercial launch strategy, market access optimization, and post-market surveillance. With a contracted backlog of $31.1 billion as of Q4 2024 in its R&DS segment alone, IQVIA demonstrates strong client demand and long-term revenue visibility. The company's global footprint, domain expertise, technology capabilities, and comprehensive data assets position it as a critical partner in addressing healthcare's most pressing challenges, from accelerating drug development timelines to improving patient outcomes and optimizing healthcare delivery. Under the leadership of Chairman and CEO Ari Bousbib, who has guided the company since the 2016 merger, IQVIA continues to invest in emerging capabilities in AI, real-world evidence, decentralized trials, and patient engagement, ensuring its position at the forefront of healthcare innovation.